KYMREarnings•globenewswire•
Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update
Sentiment:Positive (70)
Summary
Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 11, 2025 by globenewswire